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Abstract 
 
Expanded  pharmacist  prescribing  is  a  new  professional 
practice  area  for  pharmacists.  Currently,  Australian 
pharmacists’  prescribing  role  is  limited  to  over-the-counter 
medications.  This review aims to identify Australian studies 
involving  the  area  of  expanded  pharmacist  prescribing. 
Australian  studies  exploring  the  issues  of  pharmacist 
prescribing were identified and considered in the context of 
its  implementation  internationally.  Australian  studies  have 
mainly focused on the attitudes of community and hospital 
pharmacists  towards  such  an  expansion.  Studies  evaluating 
the views of Australian consumers and pharmacy clients were 
also considered. The available Australian literature indicated 
support  from  pharmacists  and  pharmacy  clients  for  an 
expanded  pharmacist  prescribing  role,  with  preference  for 
doctors  retaining  a  primary  role  in  diagnosis.  Australian 
pharmacists  and  pharmacy  client’s  views  were  also  in 
agreement in terms of other key issues surrounding expanded 
pharmacist  prescribing.  These  included  the  nature  of  an 
expanded prescribing model, the need for additional training 
for pharmacists and the potential for pharmacy clients gaining 
improved medication access, which could be achieved within 
an  expanded  role  that  pharmacists  could  provide.  Current 
evidence  from  studies  conducted  in  Australia  provides 
valuable  insight  to  relevant  policymakers  on  the  issue  of 
pharmacist  prescribing  in  order  to  move  the  agenda  of 
pharmacist prescribing forwards. 
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Introduction 
The traditional role of the pharmacist is rapidly evolving. 
Pharmacists  are  developing  skills  and  expertise  in 
evidence  based  practice  and  patient  care  which  are 
enabling  them  to  assume  new  roles  with  a  focus  on 
patient  care.
1,2  One  of  these  expanded  roles  is 
prescribing.  In  some  countries,  including  Australia, 
medications  previously  only  prescribed  by  medical 
practitioners  can  now  also  legally  be  prescribed  by 
pharmacists.
1,3,4  There  is  evidence  suggesting  that 
expanded  pharmacist  prescribing  may  in  fact  formalize 
already existing practices.
5,6,7 A recent worldwide survey 
of  hospitals  in  85  countries  indicated  that  pharmacists 
often  prescribed  medications  under  specific 
circumstances.
8,9  Findings  of  an  Australian  study  also 
confirmed this, by indicating that de facto prescribing was 
undertaken by 37% of their study participants who were 
hospital  pharmacists.
10  Potential  benefits  of  expanded 
pharmacist  prescribing  have  included:  improvement  of 
patient care, improved access to medication, optimisation 
of  medication  management  and  better  resource 
utilization.
1,6,11 Evidence from the recent introduction of 
pharmacist  prescribing  in  the  United  Kingdom  (UK)  has 
suggested  improved  patient  management.
12  One  study 
has  reported  improved  adherence  to  drug  dosing 
guidelines  with  pharmacist  supplementary  prescribers 
whereas  another  reported  that  doctors  believed 
pharmacist  supplementary  prescribing  can  reduce  their 
workload  and  errors.
13,14  Support  has  been  consistent 
since  even  some  decades  ago  there  was  evidence  in 
support of pharmacists’ prescribing skills.
15,16  
 
 
International developments 
 
A  role  in  expanded  pharmacist  prescribing  is  emerging 
internationally in various stages with the UK leading the 
way having introduced both supplementary (commenced 
in 2003) and independent models (commenced in 2006) 
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of prescribing.
6,11,17-20 An improvement in patients’ access to 
medicines, better utilisation of pharmacists’ skills,  as well as 
easing  the  burden  of  GPs  were  the  main  objectives  for 
introducing  expanded  prescribing  for  pharmacists  in  the 
UK.
6,11,17,18,21,22  
In a supplementary prescribing model there is a partnership 
between  an  independent  prescriber  (i.e.  doctor)  and  the 
pharmacist.  This  partnership  aims  to  implement  an  agreed 
patient specific clinical management plan where doctors make 
the  diagnosis  while  pharmacists  prescribe  according  to  the 
agreed plan.
1,5,17,21 In an independent prescribing model the 
pharmacist  assumes  the  full  responsibility  for  patients’ 
assessment, diagnosis and clinical management.
1,22   It should 
be noted that the English Health Department emphasised that 
pharmacist  independent  prescribers  must  only  prescribe 
within their level of competency in accordance with guidelines 
published by the Royal Pharmaceutical Society of Great Britain 
(RPSGB).
22  According  to  the  RPSGB  standards,  pharmacists 
should separate dispensing from prescribing. 
The  introduction  of  an  independent  prescribing  model  for 
pharmacists  in  the  UK  has  occurred  alongside  an  existing 
supplementary model and was not designed to replace the 
supplementary  model.  The  supplementary  model  was 
considered  suitable  for  new  pharmacist  prescribers  and  for 
pharmacists working within a healthcare team.
11 It was also a 
suitable  model  for  pharmacists  working  with  patients  with 
chronic  conditions  such  as  cardiovascular  disease  and 
diabetes.  Therefore,  this  model  is  intended  to  have  a 
continued role in the UK healthcare system.
11  
Pharmacists  in  the  USA  are  involved  in  limited  prescribing 
roles with Collaborative Drug Therapy Management (CDTM) 
being the most advanced model adopted for pharmacists. In 
this model the doctor diagnoses, while the pharmacist selects, 
initiates,  monitors,  modifies  and  continues  or  discontinues 
therapy accordingly.
1,23,24 This form of pharmacist prescribing 
is authorised in 45 states in America.
8,25-27 The main difference 
between this model and the UK supplementary  prescribing 
model  is  that  for  the  CDTM  model  there  is  a  generic 
management plan for patients whereas the UK supplementary 
model involves a specific clinical management plan for each 
patient.
5 
Over  the  past  decade  Canada  has  seen  major  progress 
towards an expansion of pharmacists’ prescribing roles. The 
main objective of pharmacist prescribing in Canada has been 
to improve patients’ health through optimising pharmacists’ 
knowledge and expertise.
8 Currently different provinces are in 
various  stages  of  granting  expanded  prescribing  roles  to 
pharmacists  but  most  of  them  have  passed  legislation 
enabling  implementation  of  some  type  of  prescribing.
8  
Prescribing models in place allow pharmacists to renew and 
adapt a prescription, prescribe in emergency situations  and 
initiate or manage drug therapy. 
8,28 In addition to a variation 
in prescribing authority granted to pharmacists, there are 
also  different  requirements  for  pharmacists  gaining 
prescribing rights. It should be emphasised that controlled 
drugs and narcotics are not allowed to be prescribed by 
pharmacists.
28 
 
In  New  Zealand  any  registered  health  professional 
including pharmacists can enter into dependent forms of 
prescribing  such  as  protocols  and  ‘standing  orders’.
1 
Recently the agenda for expanded pharmacist prescribing 
has  progressed.  The  Pharmacy  Council  of  New  Zealand 
(PCNZ)  has  successfully  completed  consultations  with 
stakeholders regarding a proposed ‘pharmacist prescriber 
scope  of  practice’.
29  These  consultations  indicated  a 
strong  support  by  stakeholders  regarding  the  proposed 
scope. This proposed model of practice allows qualified 
experienced clinical pharmacists to prescribe prescription 
medicines including controlled drugs when working in a 
collaborative healthcare team environment. The PCNZ has 
explicitly  forbidden  pharmacist  prescribers  to  dispense 
their  prescriptions  or  have  a  financial  interest  in  a 
pharmacy.
29 An application has already been made by the 
Council  to  the  Health  Workforce  New  Zealand  for 
pharmacists to gain prescribers’ status and a decision is 
expected in due course.
29  
Australian perspective 
 
Pharmacists in Australia currently prescribe medications 
listed under Schedules 2 (S2) and 3 (S3) of the Standard 
for  the  Uniform  Scheduling  of  Medicines  and  Poisons 
(SUSMP).  These  medicines  are  available  OTC  only  from 
community  pharmacies  (except  in  exceptional 
circumstances such as isolated communities). Australian 
pharmacists  are  also  able  to  continue  the  supply  of 
prescription  only  medications  based  on  ‘emergency 
supply’  and  ‘repeat  prescription’  systems.  The  repeat 
system of prescribing allows pharmacists to continue to 
re-fill doctors’ initial prescriptions usually monthly for up 
to 12 months, dependent on the medication and when 
authorised by the doctor. It should be noted that non-
medical  prescribing  in  Australia  has  already  been 
expanded  to  include  dentists,  optometrists, 
physiotherapists, podiatrists and nurses. 
 
 
a)  Studies exploring pharmacists’ views 
A  number  of  studies  on  the  issue  of  pharmacist 
prescribing  have  been  conducted  in  Australia.    A 
descriptive  study  addressed  the  awareness  of 
international developments in pharmacist prescribing and 
whether  respondents  would  benefit  from  prescribing 
activities.
30 Views of Australian hospital pharmacists were  Australasian Medical Journal AMJ 2011, 4, 4, 236-242 
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assessed in another study.
31 Both studies, although limited in 
representativeness,  reported  support  by  pharmacists  for 
expanding their prescribing role. A survey of a large number of 
hospital pharmacists in Australia found that development of a 
collaborative prescribing model would be well supported and 
could improve hospital services by their provision in a more 
timely  manner.
10  According  to  these  authors,  hospital 
pharmacists  indicated  support  for  prescribing  within  their 
competency with most pharmacists considering prescribing in 
a specialised clinical area.
10 Another recent study in Australia 
piloted  a  UK  non-medical  prescribing  course  and  also 
evaluated  Australian  hospital  pharmacists’  views  on  non-
medical prescribing.
32 These authors reported some positive 
and negative themes regarding training experiences of their 
participants.
32  Expanded  pharmacist  prescribing  was  viewed 
positively.  In  this  study,  participants  were  not  comfortable 
with  the  term  ‘independent  prescribing’  mainly  due  to 
potential perceived reaction from doctors. Potential barriers 
such  as  time  management  and  work  pressure  were  also 
identified.
32 
 
Bessell  et  al.  proposed  four  models  which  would  allow 
pharmacists to perform expanded prescribing roles.
34 These 
models  were:  i)  medicine  maintenance  (a  collaborative 
approach  allowing  pharmacists  to  prescribe  according  to  a 
patient-specific  plan  designed  by  the  doctor  for  patients  in 
Residential Aged Care Facilities), ii) advanced practitioner (a 
model which would allow hospital pharmacists to prescribe 
medicines  in  a  supplementary  fashion),  iii)  protocol 
management  (a  model  which  would  allow  pharmacists  to 
prescribe  prescription  medicines  according  to  a  ‘defined 
population-based protocol’) and iv) formulary prescribing (an 
advanced  version  of  currently  available  S3  prescribing  in 
community  pharmacies  allowing  pharmacists  to  claim 
currently  prescribed  S3  medicines  via  the  Pharmaceutical 
Benefits Scheme). 
33  
A  study  conducted  by  Hoti  et  al. 
34  explored  Australian 
pharmacists’  attitudes  on  different  aspects  of  pharmacist 
prescribing. This was the first major study which examined the 
views of a large sample of Australian pharmacists and found 
an overwhelming support for an expanded prescribing role. 
This  support  was  not  dependent  on  respondents’  location, 
gender,  professional  practice  area,  years  of  registration  as 
pharmacists or pharmacy ownership.
34,35  This  study showed 
that a vast majority of respondents indicated they would need 
further training in order to assume further prescribing roles. 
The major reasons cited for expanding the pharmacist scope 
of  prescribing  included  better  utilization  of  pharmacists’ 
professional skills, easing of the burden from overloaded GPs 
and  pharmacists’  drug  knowledge.
34  Improved  access  to 
medications  for  patients  was  also  an  important  potential 
driver to expanding pharmacists’ prescribing role.
34 This study 
reported  that  currently,  inadequate  training  in  disease 
diagnosis  followed  by  inadequate  training  in  patient 
assessment  and  monitoring  were  perceived  to  be  the 
strongest barriers to expanded pharmacist prescribing in 
Australia.
34 This study also identified potential drivers to 
expanded pharmacist prescribing.
34 
 
In terms of pharmacist prescribing models preferred, Hoti 
et al. reported that a majority of pharmacists preferred 
prescribing in a supplementary model.
34 Respondents who 
supported  only  an  independent  prescribing  model 
indicated preference for prescribing only in the areas of 
pain management, a limited range of infections and to a 
lesser  extent  asthma.  More  therapeutic  areas  of 
prescribing  were  preferred  by  supporters  of  a 
supplementary prescribing model.
34 This study also found 
that  both  supplementary  and  independent  prescribing 
models  were  positive  predictors  of  expanding 
pharmaceutical  services  through  prescribing  with  the 
supplementary  prescribing  being  more  strongly 
associated.
34 
Hoti et al. explored basic infrastructural implications for 
accommodating an expanded pharmacist prescribing role. 
It was found that a majority of respondents believed that 
additional IT resources were needed and also considered 
that  prescribing  and  dispensing  should  carried  out 
separately. Only a third of respondents considered they 
have sufficient access to patient information.
35 
 
 
b)  Studies exploring patients’ views 
There is a limited amount of literature data focused on 
exploring  the  attitudes  of  one  of  the  key  stakeholders 
involved in pharmacist prescribing, that is, patients. 
1,6,11,36  
In the UK, studies have thus far considered the attitudes 
of  the  general  public  and  patients  who  had  already 
experienced  expanded  pharmacist  prescribing.  These 
studies  have  reported  support  and  benefits  from  this 
role.
37,38,39,40  
In  Australia,  Bessell  et  al.  also  explored  consumers’ 
perspectives.  These  authors  indicated  that  consumers 
were  supportive  of  improved  access  to  medications.
33 
Hoti et al. reported the views of pharmacy clients who 
regularly filled at least one prescription medication from a 
pharmacy and had not experienced expanded pharmacist 
prescribing.
41  This  study  found  that  a  vast  majority  of 
pharmacy clients indicated high levels of satisfaction with 
current  professional  services  offered  by  pharmacists  as 
well  as  their  drug  knowledge.
41  Pharmacy  clients  had 
positive views in terms of them trusting pharmacists to 
assume further prescribing roles but felt comfortable with  Australasian Medical Journal AMJ 2011, 4, 4, 236-242 
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this  role  only  if  the  diagnosis  had  been  initially  made  by a 
doctor. 
41 
One  third  of  respondents  indicated  that  they  would  accept 
pharmacists both diagnosing and prescribing for the condition 
diagnosed. Pain management followed by anti-infectives were 
the  only  areas  that  this  group  of  respondents  supported 
pharmacists  both  diagnosing  and  prescribing.  A  majority  of 
pharmacy  clients  indicated  that  pharmacists  would  need 
further  training  in  order  to  assume  additional  prescribing 
roles.
41 
The importance of improved medication access to medicines, 
highlighted by Bessell et al. was also confirmed by Hoti et al. 
who  found  that  pharmacy  clients  considered  that  their 
medication  access  would  be  improved  if  pharmacists  had 
expanded  prescribing  roles  (67%  agreed/strongly  agreed).
41 
Furthermore,  improved  medication  access  was  found  to  be 
the  strongest  positive  predictor  of  pharmacy  clients’ 
perception  of  trust  to  expanded  pharmacist  prescribing 
followed by the supplementary model of prescribing and then 
the independent model of prescribing.
41 Hoti et al. also found 
that the Agency theory can be used in the area of pharmacist 
prescribing in further understanding the relationship between  
principals  (i.e.  pharmacy  clients)  and  agents  who  perform 
actions  on  their  behalf  (i.e.  doctors  and  pharmacists).
41,42 
These authors cautioned that the introduction of an expanded 
prescribing role for pharmacists, according to this theory, may 
disrupt the existing relationship between doctors and patients 
and  recommended  that  this  role  for  pharmacists  be 
introduced in a way that facilitates this existing relationship.
41 
 
This study also indicated that almost half of the respondents 
were willing to pay a fee to pharmacists for their prescribing 
services  whilst the community pharmacy was the preferred 
location for pharmacist prescribers (as opposed to their own 
office or GP’s surgery).
35,41  
 
Consideration of expanded pharmacist prescribing in Australia 
seems to be more advanced in the state of Queensland were 
there  are  currently  two  trials  in  the  implementation  stage 
being  conducted.  These  trials  are  exploring  the  skills, 
knowledge and competencies of pharmacist prescribers and 
are both being conducted in hospital settings.
43 Furthermore, 
in Queensland, approval has been granted to allow pilots of 
pharmacist prescribing.
32  
 
Discussion 
Current  evidence  suggests  that  the  uptake  of  expanded 
pharmacist prescribing in Australia is lagging behind countries 
such as the UK, USA, Canada and New Zealand.
1,6,8,10,27  The 
available  literature  on  expanded  pharmacist  prescribing  in 
Australia  has  indicated  strong  support  by  the  pharmacy 
profession  for  this  role.
10,30-32,34,41    Additionally,  Australian 
studies  have  also  suggested  that  one  of  the  key 
stakeholders  (i.e.  patients)  were  supportive  of  an 
expanded prescribing role for pharmacists with improved 
medication access to medicines being a strong driver for 
this support.
33,41  
Both  pharmacists’  and  pharmacy  clients’  views  are  in 
accordance in terms of key issues surrounding the issue of 
expanded pharmacist prescribing.
10,34,41 Pharmacists and 
pharmacy clients have indicated support for pharmacists 
having an expanded role in prescribing and both groups 
indicated  strongest  support  for  a  prescribing  model  in 
which  doctors  retained  their  primary  role  in  diagnosis, 
that  is,  a  supplementary  prescribing  model.  In  both 
groups,  supplementary  and  independent  prescribing 
models were positive predictors of pharmacist prescribing 
with  a  supplementary  model  being  a  stronger 
predictor.
34,41  Weeks  et  al.  has  reported  that  a 
collaborative form of prescribing was also supported by 
hospital pharmacists.
10 These data have suggested that a 
supplementary  prescribing  model  where  doctors  retain 
their  primary  role  in  diagnosis  while  pharmacists 
prescribe collaboratively should initially be considered in 
Australia. In terms of Besssell et al. proposed models, the 
above findings by Hoti et al. and Weeks et al. suggest that 
the  ‘advanced  practitioner’  and  ‘protocol  management’ 
prescribing models, in which doctors retain their primary 
role in diagnosis, would be well received by the pharmacy 
profession in Australia.
10,33,34  
The third point of agreement between pharmacists and 
pharmacy clients reported by Hoti et al. is the therapeutic 
areas  of  prescribing.
34,41  When  an  independent 
prescribing model only was supported by pharmacists and 
pharmacy clients, therapeutic areas of pain management 
and a limited number of infections were the major areas 
of prescribing supported (with asthma following in both 
groups).  These  findings  should  be  interpreted  whilst 
considering  the  significance  of  improved  access  to 
medicines in relation to expanded pharmacist prescribing 
reported by both Bessell et al. and Hoti et al. Improved 
access to medicines for a limited range of infections and 
pain  management  may  be  more  relevant  during  after 
hours, weekend and in rural areas and this highlights the 
need  for  further  research  which  would  evaluate  the 
impact  of  expanded  pharmacist  prescribing  in  these 
specific  circumstances.  Finally,  both  pharmacists  and 
pharmacy  clients  considered  that  further  training  is 
needed for pharmacists to assume additional prescribing 
roles, with Weeks et al. reporting that this training should 
be customised to the Australian setting. 
32,34,41 
 
The views of the medical profession in Australia regarding 
expanded pharmacist prescribing have thus far not been  Australasian Medical Journal AMJ 2011, 4, 4, 236-242 
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researched.  However,  the  Australian  Medical  Association 
(AMA) has in the past indicated that it does not support such a 
role for pharmacists. An AMA president has pointed out that 
“doctors  must  maintain  sole  responsibility  for  prescribing 
medicines  to  patients”.
44  This  was  a  reaction  to  a  limited 
pharmacist prescribing extension proposed by the Pharmacy 
Guild  of  Australia  (PGA),  of  a  list  of  20  medicines  that 
pharmacists should be able to prescribe. Patient safety, lack of 
pharmacist training and a conflict of interest with pharmacists 
having  both  dispensing  and  prescribing  rights  were 
emphasized as the main reasons in AMA’s stance.
44 However, 
it should be noted that the Pharmaceutical Society of Australia 
and Society of Hospital Pharmacists of Australia (SHPA) have 
already indicated that prescribing and dispensing roles should 
be  separated.
45,46  It  should  be  noted  that  most  health 
professionals  have  already  established  limited  independent 
non-medical prescribing rights in Australia. The UK experience 
with  supplementary  prescribing  suggests  that  doctors  had 
positive  views  post-introduction  of  this  form  of 
prescribing.
14,47  
 
The  available  Australian  literature  has  also  identified  that 
pharmacists  and  pharmacy  clients  prefer  doctors  retaining 
their  primary  role  in  disease  diagnosis.
10,34,41  This,  together 
with  a  close  collaboration  between  doctors  and 
supplementary pharmacist prescribers, may address doctors’ 
concerns  regarding  patients’  safety  while  patients  take 
advantage  of  the  potential  benefits  of  an  expanded 
prescribing  role  for  pharmacists.
1,6,11-14  A  supplementary 
prescribing  model  could  be  implemented  in  Australia  in  a 
different  form  to  that  in  the  UK.  This  model  could  be 
customized  to  Australian  settings  whilst  taking  into 
consideration potential limitations of the UK supplementary 
prescribing  model  reported,  such  as  those  involved  around 
the use of clinical management plans.
6,11,12,48 Considering the 
UK experience with this model of prescribing, an introduction 
of  such  a  model  in  Australia  could  also  result  in  beneficial 
outcomes for patients.
1,11,12 
 
The  concern  regarding  pharmacists’  training  was  also 
addressed by Australian pharmacists (and pharmacy clients) 
who overwhelmingly indicated they needed further training 
before  additional  prescribing  roles  were  assumed.
35  In 
addition, the SHPA’s position on prescribing by non-medical 
professionals  is  that  “only  health  professionals  who  have 
undergone credentialing within their defined practice setting, 
in pharmacology, pharmacokinetics and applied therapeutics, 
meeting  the  standard  core  competencies  for  safe  and 
effective  prescribing,  should  be  registered  to  prescribe 
medicines following diagnosis”.
45 
 
 
Conclusion 
Research data on pharmacist prescribing in Australia, has 
reported  that  pharmacists’  and  their  clients’  views  are 
strongly  positive  towards  expanded  pharmacist 
prescribing. These data provides considerable insight for 
the  relevant  policymakers  in  order  for  the  agenda  of 
expanded pharmacist prescribing to be moved forward. 
Further  research  assessing  pharmacist  prescribing  roles 
for a limited range of infections and pain management 
should  be  the  next  step.  In  addition,  the  role  of 
pharmacist prescribing in rural settings, after hours and 
weekend periods should be  considered.  There is also a 
need  for  research  assessing  the  views  of  the  medical 
profession  in  Australia  on  the  issue  of  pharmacist 
expanded  prescribing.  Currently  available  Australian 
studies indicated that both pharmacists and their clients 
prefer expanded pharmacist prescribing being carried out 
in collaboration with doctors, while doctors retain their 
primary role in diagnosis. An introduction of pharmacist 
prescribing  should  take  into  consideration  the  need  to 
preserve  existing  relationship  between  doctors  and 
patients. 
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